REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai > Cyclopeptides > 16 To 24 Peptide Repeating Units In Known Peptide Chain 16 To 24 Peptide Repeating Units In Known Peptide Chain16 To 24 Peptide Repeating Units In Known Peptide Chain patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027087 - Methods for preventing mitochondrial permeability transition The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of ... 02/01/07 - 20070027086 - Melanocortin 1 receptor selective compounds to a patient or a healthy individual. ... 01/18/07 - 20070015711 - Methods for reducing oxidative damage The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three ... 01/18/07 - 20070015710 - Cyclosporin compositions A composition comprising from 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil selected from the group consisting of anise oil, clove oil, cassia oil, cinnamon oil, and combinations thereof, wherein said composition is an ophthalmically acceptable emulsion is disclosed herein. ... 01/11/07 - 20070010450 - Methods and compositions for the treatment of gastrointestinal disorders Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and ... 01/04/07 - 20070004631 - Method for synthesis of phospholipids-peg-biomolecule conjugates The present invention relates to methodology of manufacturing phospholipids-PEG-biomolecule conjugates suitable for use as a component of diagnostic or therapeutic liposomes/micelles in targeted diagnostics or therapy and concerns specifically a simple method of synthesis, purification and analysis of phospholipid biomolecule, e.g. peptide, conjugates. The invention thus provides micellar peptides, which ... 12/21/06 - 20060287238 - Novel combinations of dnak inhibitors with known antibacterial agents Compositions, methods and kits are provided comprising (a) a therapeutically effective amount of a DnaK inhibitor; and (b) a therapeutically effective amount of a known antibacterial agent. Such compositions, methods and kits are useful in the treatment of various bacterial infections. ... 12/14/06 - 20060281682 - Methods and compositions for the treatment of gastrointestinal disorders The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction ... 12/07/06 - 20060276400 - Modulation of cholesteryl ester transfer protein (cetp) activity The present invention relates to autoantigenic vaccine peptides comprising a universal helper T cell epitope portion linked to a B cell epitope portion from the N-terminus of cholesteryl ester transfer protein (CETP). The vaccine peptides are useful for eliciting an autoimmune response in a vaccinated individual, i.e., raising antibodies against ... 11/16/06 - 20060258592 - Materials and methods for regulating blood flow The subject invention provides materials and methods useful in regulating blood flow. In a preferred embodiment, the subject invention provides peptides that are able to enhance nitric oxide (NO) activity and/or elevate cellular guanosine monophosphate (cGMP). Through these mechanisms, the subject invention can be used advantageously to effect vasorelaxation, thereby ... 11/09/06 - 20060252697 - Compounds that bind to growth hormone receptor The present invention provides peptides that bind to the active site of the growth hormone receptor. The present invention also provides methods of using these peptides to identify small organic molecules, which are novel agonists or antagonists of the growth hormone receptor. In addition, the present invention provides kits and ... 11/02/06 - 20060247175 - Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient Human myelin basic protein (h-MBP) has a molecular weight of 18.5 KD and contains 170 amino acid residues. Synthetic peptides ranging in length from about 8 to 25 residues and covering the entire length of the protein have been produced. Antibodies to h-MBP (anti-MBP) were found to be neutralized by ... 10/26/06 - 20060241050 - Inhibiting furin with polybasic peptides Small, polybasic peptides are disclosed that are effective as furin inhibitors, e.g. hexa- to nona-peptides having L-Arg or L-Lys in most positions. Removing the peptide terminating groups can improve inhibition of furin. High inhibition was seen in a series of non-amidated and non-acetylated polyarginines. The most potent inhibitor identified to ... 10/26/06 - 20060241049 - Use of thrombin-derived peptides for the therapy of chronic dermal ulcers Disclosed is a method of promoting healing of a chronic dermal skin ulcer, such as a diabetic ulcer, on a subject. The method comprises the step of contacting the chronic dermal skin ulcer with an effective amount of an agonist of the non-proteolytically activated thrombin receptor. ... 10/26/06 - 20060241048 - Modified therapeutic agents The invention provides a modified therapeutic agent, said modified agent comprising three or more membrane binding elements with low membrane affinity covalently associated with the agent which elements are capable of interacting independently and with thermodynamic additivity, with components of cellular or artificial membranes exposed to extracellular fluids wherein at ... 10/19/06 - 20060234940 - Secondary binding site of dipeptidyl peptidase iv (dp iv) The present application relates to the secondary binding site of dipeptidyl peptidase IV, its relationship amongst substrates and to the modulation of substrate specificity of dipeptidyl peptidase IV (DP IV, synonym: DPP IV, CD26, EC 3.4.14.5). The application relates further to compounds that bind to the secondary binding site of ... 10/19/06 - 20060234939 - Methods of using ziconotide to treat overactive bladder The invention relates to methods of using Cav2.2 subunit calcium channel modulators to treat painful and non-painful lower urinary tract disorders and the related genitourinary tract disorders vulvodynia and vulvar vestibulitis in normal and spinal cord injured patients. ... 10/19/06 - 20060234938 - Peptides impairing pbx dependent gene regulation X7 is an amino acid with a basic side chain or Serine; in the manufacture of a medicament for treating or preventing a disorder in which aberrant cell division occurs. ... 10/12/06 - 20060229249 - Peptide substrates of a proteolytic adam33 polypeptide and assays using the same The present invention discloses peptide substrates of a proteolytic ADAM33 polypeptide. The present invention also discloses methods of identifying additional substrates of a proteolytic ADAM33 polypeptide. Furthermore, the present invention discloses methods of identifying compounds that inhibit the proteolytic activity of a proteolytic ADAM33 polypeptide. ... 10/05/06 - 20060223755 - Peptide inhibitors of toxins derived from ll-37 The present invention relates to a group of peptidic compounds which have affinity for toxins and especially for bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. These compounds can inhibit or neutralize the toxins. In addition, the present invention relates to the use of these compounds as therapeutic or diagnostic ... 09/21/06 - 20060211623 - Conopeptides The invention relates to novel conopeptides and/or novel Luses of conopeptides. The conopeptides of the invention are analogs of α-Conotoxin MII that are selective for α6-containing nAChRs as described herein. ... 09/14/06 - 20060205665 - Intracellular delivery of biological effectors The invention relates to a sequence of amino acids with the capacity to facilitate transport of an effector across a biological membrane. More specifically, the present invention relates to novel peptide transporters that specifically target certain cell types for the intracellular delivery of drugs and therapeutic agents. ... 09/14/06 - 20060205664 - Mucin hypersecretion inhibitors and methods of use Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 23 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to ... 09/14/06 - 20060205663 - Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof Methods of producing lung surfactant formulations through solvent dissolution and lyophilization are described as well as surfactant formulations derived therefrom. Methods of treating respiratory distress dysfunction are also provided. ... 08/24/06 - 20060189537 - Peptides for detection of antibody to ehrlichia ewingii The invention provides compositions and methods for the detection and quantification of Ehrlichia ewingii, Ehrlichia ewingii antibodies, antibody fragments, and polypeptides. ... 08/17/06 - 20060183688 - Peptide interacting with anti-apoptotic proteins of the bcl-2 family The invention relates to the identification of a new peptide interacting with the anti-apoptotic proteins Bcl-2, Bcl-W and/or Bcl-XL, and also to screening methods allowing identification of modifiers of those interactions. ... 08/03/06 - 20060172948 - Gamma-carboxyglutamate containing conopeptides The invention relates to γ-carboxyglutamate containing conopeptides, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding ... 08/03/06 - 20060172947 - Physiologically active peptides and drugs containing the same A peptide having any one of the amino acid sequences of SEQ ID NO: 1 or 13, preferably a peptide having any one of the amino acid sequences of SEQ ID NOS: 2 to 9 or a peptide having any one of the amino acid sequences of SEQ ID NOS: ... 07/27/06 - 20060166888 - Leukocyte stimulating peptides The present application describes peptides that stimulate arachidonic acid release in target cells. The application also discloses peptides that cause intracellular calcium release. ... 07/13/06 - 20060154871 - Peptides The amino acid sequence of several peptides present in Colostrinin is disclosed. These peptides are useful, inter alia, in the treatment of disorders of the immune system and the central nervous system. ... 07/06/06 - 20060148713 - Use of exendins and agonists thereof for the reduction of food intake Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or ... 07/06/06 - 20060148712 - Monocyte chemoattractant activity of galectin-3 Inhibitors of galectin-3 expression or activity, for administering to a subject in an amount sufficient to reduce or decrease onset, progression, severity, frequency, duration or probability of one or more symptoms associated with asthma, among other respiratory airway and respiratory mucosal disorders. ... 07/06/06 - 20060148711 - Molecular interactions in neurons Inhibitors that disrupt binding between a PDZ protein and cognate ligands such as N-methyl-D-aspartate (NMDA) receptors that are involved in various neurological disorders are provided. Pharmaceutical compositions containing such inhibitors and their use in treating neurological diseases such as stroke and ischemia are also disclosed. Screening methods to identify additional ... 07/06/06 - 20060148710 - Oligopeptides, composition and use thereof as elicitors of the natural defences of plants The invention relates to oligopeptides used as elicitors of the natural defences of plants in order to control fungal and/or bacterial and/or viral pathogens and/or crop pests, by means of foliar or root application or by injection. According to the invention, said oligopeptides are characterised in that they are obtained ... 06/22/06 - 20060135430 - Bly antagonists and uses thereof The present invention relates to polypeptides that block BLyS signaling, nucleic acid molecules encoding the polypeptides, and compositions comprising the polypeptides. The present invention also relates to methods for treating an immune-related disease or cancer using the polypeptides and compositions of the invention. The present invention also relates to methods ... 06/01/06 - 20060116325 - Methods and compositions for inhibiting hiv-coreceptor interactions Novel methods and compositions are provided for inhibiting interactions between human immunodeficiency viruses (HIVs) and viral coreceptors, including CXCR4 and/or CCR5 coreceptors. The anti-coreceptor binding agent includes a novel peptide portion of the gp120 envelope protein of HIV-1, as well as peptide analogs and mimetics of this peptide, that specifically ... 05/18/06 - 20060105956 - Phenotypic reversion of pancreatic carcinoma cells The present invention provides peptides (including analogs and derivatives thereof) corresponding to residues 96-110 and 35-47 of ras-p21, which peptides have attached thereto a membrane-penetrating leader sequence. The subject peptides, analogs and derivatives thereof are useful in treatment of cancers and have been shown to induce phenotypic reversion of pancreatic ... 05/04/06 - 20060094659 - Antagonist peptides to the c5a chemotactic function of vitamin d binding protein It has been demonstrated that one of Vitamin D Binding Protein (DBP) biological functions is to enhance the chemotactic activity of C5a and C5a des Arg. The present invention has found that peptides having sequences that substantially correspond to a specific region in the N-terminal domain I of DBP can ... 05/04/06 - 20060094658 - Method and compositions for the treatment of gastrointestinal disorders Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and ... 04/20/06 - 20060084607 - Purified amphiphilic peptide compositions and uses thereof A plurality of amphiphilic peptide chains having alternating hydrophilic and hydrophobic amino acids, wherein the peptide contains at least 8 amino acids, are complementary and structurally compatible, and self-assemble into a beta-sheet macroscopic scaffold wherein peptide at least about 75% of the chains have the same sequence. ... 04/20/06 - 20060084606 - Methods for reducing oxidative damage The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three ... 03/30/06 - 20060069030 - Apolipoprotein a1 mimetics and uses thereof The present invention provides peptidomimetics derived from Apolipoprotein A-I, which is useful for beneficially influencing lipid parameters and/or plasma cholesterol levels. The invention also provides pharmaceutical compositions and methods of treatment for elevated levels of plasma cholesterol. ... 03/16/06 - 20060058240 - Peptides and compounds that bind to a receptor Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide ... 02/23/06 - 20060040866 - Peptides and compounds that bind to a receptor Peptides and compounds that bind to and activate the thrombopoietin receptor (c-mpl or TPO-R) or otherwise act as a TPO agonist are disclosed. ... 02/02/06 - 20060025344 - Ghrelin receptor inverse agonists for regulation of feeding behaviors Compounds of the invention act as inverse agonist ghrelin receptors. Some of the compounds of the invention may have both inverse agonistic and antagonistic properties as they both decrease or eliminate the constitutive activity of he ghrelin receptor and block the effect of ghrelin. Other preferred compounds of the invention ... 01/26/06 - 20060019900 - Alpha-4 beta-1 integrin ligands for imaging and therapy The present invention provides α4β1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unnatural amino acid or a D-amino acid, and wherein n is an integer of from 3 ... 01/12/06 - 20060009391 - Method and peptide for regulating cellular activity Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an inflammatory response in a subject. ... 01/05/06 - 20060003939 - Peptides and methods for cell death regulation The present invention provides novel peptides, nucleic acids, compounds, compositions and methods for regulating apoptosis, and screening methods for identifying same. Regulation of apoptosis is mediated via IAPi-derived proteins, peptide fragments thereof, and nucleic acids encoding same, stimulating/accelerating or downmodulating/suppressing apoptosis. For stimulation/acceleration of apoptosis, the IAPi-derived proteins or peptide ... 12/22/05 - 20050282754 - Peptides and peptide analogues designed from hfe protein and their uses in the treatment of iron overload diseases The present invention relates to peptides and peptide analogues designed from HFE protein. In particular, it relates to peptides and peptide analogues designed from an alpha-1 region of HFE protein which lowers the binding affinity of transferrin receptor for transferrin. Such compounds mimic HFE protein function, and reduce iron uptake ... 12/08/05 - 20050272660 - Polypeptide derivatives of parathyroid hormone (pth) Novel parathyroid hormone (PTH) polypeptide derivatives are disclosed, as are pharmaceutical compositions containing said polypeptides, and synthetic and recombinant methods for producing said polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing said polypeptides. Also disclosed are methods ... 12/08/05 - 20050272659 - Helical peptidomimetics with enhanced activity Helical peptidomimetic compounds as inhibitors of beta-amyloid production are provided. These inhibitors have sequences with lengths from 11 to 16 amino acids, inclusive. These inhibitors potently inhibit intramembrane proteases, notably aspartyl secretases involved in the enzymatic cleavage of amyloid precursor protein (APP) to yield amyloid-β-peptide. Methods are provided for making ... 12/08/05 - 20050272658 - Applications of peptides derived from the cytoplasmic domain of amyloid precursor protein (app) The invention concerns novel uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (APP); said peptides are in particular sequences including the membrane domain juxtaposed to the cytoplasmic domain of the amyloid protein precursor (APP) (one-letter code), selected in the group consisting of the sequences Y1KQYTSIHHGY0 ... 12/01/05 - 20050267035 - Peptide and polypeptide inhibitors of complement c1s The complement system plays an important role in providing resistance to infections and in the pathogenesis of tissue injury. Yet an inappropriate activation of complement can result in a variety of disorders. The present invention provides C1s catalytic site-directed moieties, C1s exosite binding moieties, and bivalent polypeptide inhibitors comprising such ... 11/24/05 - 20050261193 - Antimicrobial theta defensins and methods of using same The present invention relates to an isolated cyclic peptide, theta defensin, having antimicrobial activity, and to theta defensin analogs. A theta defensin can have the amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa1-Xaa6-Xaa4-Xaa4-Xaa1-Xaa1-Xaa6-Xaa4-Xaa5-Xaa1-Xaa3-Xaa7-Xaa5, wherein Xaa1 to Xaa8 are defined; wherein Xaa1 can be linked through a peptide bond to Xaa8; and wherein crosslinks can ... 11/10/05 - 20050250699 - Antimicrobial polypeptides The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides. ... 11/03/05 - 20050245452 - Pharmaceutical use of novispirins The present invention relates to use of Novispirin antimicrobial polypeptides in preparation of a pharmaceutical composition suitable for use against microbial lung infections or skin infections or for use in promoting wound healing. ... 11/03/05 - 20050245451 - Peptides selectively lethal to malignant and transformed mammalian cells The present invention provides peptides corresponding to all or a portion of amino acid residues 12-26 of human p53 protein, which peptides are lethal to malignant or transformed cells when fused to a membrane-penetrating leader sequence. In order to reduce proteolysis of a subject peptide, one or more D-amino acids ... 10/27/05 - 20050239710 - Anti-aging and wound healing compounds The invention provides inhibitors of matrix metalloproteinases that are useful for encouraging the development of healthy skin and for treating wounds. The inhibitors are peptides having sequences related to cleavage regions of the proenzyme forms of matrix metalloproteinases. The peptide inhibitors of the invention can be formulated into therapeutic compositions, ... 10/27/05 - 20050239709 - Synthetic antimicrobial polypeptides The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides. ... 10/13/05 - 20050227923 - Stimulation of bone growth with thrombin peptide derivatives Disclosed is a method of stimulating bone growth at a site in a subject in need of osteoinduction. The method comprises the step of administering a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor to the site. ... 10/13/05 - 20050227922 - Neuroprotective dietary supplement The invention relates to a novel dietary supplement mixture having improved neuroprotective activity and preventing, ameliorating or counteracting neurodegeneration and preventing, counteracting and/or improving cognitive function decline. It also provides a dietary supplement, which is to be administered in an oral dosage form. ... 10/06/05 - 20050222035 - Peptides and related molecules that modulate nerve growth factor activity The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are ... 10/06/05 - 20050222034 - Modulation of trip-br function and method of treating proliferative disorders Methods for modulating TRIP-Br function and activity in a proliferating cell are provided, as well as methods for treating a proliferative disorder by modulating TRIP-Br function in a proliferating cell. ... 09/29/05 - 20050215478 - Amino acid sequences capable of facilitating penetration across a biological barrier The invention relates to amino acid sequences capable of facilitating penetration of an effector across a biological barrier. The invention also relates to methods of treating preventing diseases by administering or penetrating modules to affected subjects. ... 09/22/05 - 20050209157 - Short bioactive peptides and methods for their use Short bioactive peptides containing phenylalanine, leucine, alanine, and lysine residues are disclosed. The peptides can be used in antibacterial, antifungal, anticancer, and other biological applications. ... 09/22/05 - 20050209156 - Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients Human myelin basic protein (h-MBP) has a molecular weight of 18.5 KD and contains 170 amino acid residues. Synthetic peptides ranging in length from about 8 to 25 residues and covering the entire length of the protein have been produced. Antibodies to h-MBP (anti-MBP) were found to be neutralized by ... 09/22/05 - 20050209155 - Igf-binding protein-derived peptide or small molecule New compositions based on IGF-binding protein sequences are provided. New tools for high-throughput research are provided. New methods for the treatment of human disease are provided. IGFBP-3-derived peptide or small molecule is administered to subjects having disease, thereby alleviating the symptoms of the disease. ... 09/15/05 - 20050203025 - Compounds and methods for modulating nonclassical cadherin-mediated functions Modulating agents for inhibiting or enhancing nonclassical cadherin mediated cell adhesion are provided. The modulating agents comprise one or more of: (a) a peptide sequence that is at least 50% identical to a nonclassical cadherin CAR sequence; (b) a non-peptide mimetic of a nonclassical cadherin CAR sequence; (c) a substance, ... 09/15/05 - 20050203024 - Peptides and methods for inducing cellular resistance to infection This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and non-enveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral ... 07/28/05 - 20050164942 - Method for treating cytokine mediated hepatic injury A method of modulating cytokine mediated hepatic injury by administering compound-D SEQ ID NO:1 to a mammal. A concentration of the compound in the range of about 0.5 mg/kg to about 20 mg/kg in a physiologically acceptable formulation blocks a cytokine cascade. A therapeutic method of modulating cytokine mediated acute ... 07/21/05 - 20050159360 - Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases A pharmaceutical composition including at least one therapeutic molecule effective for treating lung cancers or pulmonary diseases; and at least one peptide vector that augments bioavailability of the molecule in a patient's lungs selected from the group consisting of Ala-Trp-Ser-Phe-Arg-Val-Ser-Tyr-Arg-Gly-Ile-Ser-Tyr-Arg-Arg-Ser-Arg (SynB4) (SEQ ID No. 1), and Arg-GLy-Gly-Arg-Leu-Ser-Tyr-Ser-Cit-Cit-Cit-Phe-Ser-Thr-Ser-Thr-Gly-Arg (SynB6) (SEQ ID ... 06/30/05 - 20050143309 - Alkyl peptide amides and applications Disclosed are alkyl peptide amides capable of inhibiting or reducing sperm cell motility. Methods of inhibiting or reducing sperm motility using certain alkyl peptide amides are also disclosed. ... 06/16/05 - 20050130898 - Carboxypeptidase r inhibiting peptide A novel carboxypeptidase R (CPR) inhibiting peptide is prepared using rational structure-based strategies, incorporating two principle facts: (a) CPR has a strong affinity for basic amino acids and; and (b) the two lysines and arginine residues of PCI are orientated in the same direction and held in close spatial proximity ... 06/09/05 - 20050124544 - Peptide decoys for the preparation of medicaments intended for the prevention or treatment of autoimmune pathologies or disorders linked to the appearance of antibodies directed against exogenous proteins Peptide or pseudopeptide decoys binding to antibodies capable of being developed against endogenous proteins within the framework of autoimmune pathologies or against exogenous proteins administered to patients, in particular within the framework of pathologies due to a deficiency in these proteins, the amino acid sequence of the peptide or pseudopeptide ... ### FreshPatents.com Support |